At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings…
NEW YORK, NY / ACCESSWIRE / April 7, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP ...
WILMINGTON, Del., April 27, 2020 -- Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of.
BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020COVID-19 vaccine program BNT162 set to.
NEW YORK, May 01, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice.
NEW YORK, NY / ACCESSWIRE / April 14, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh ...
NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP ...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neon Therapeutics, Inc. ("NTGN" or the "Company") (NASDAQ: NTGN) in connection with the proposed acquisition of the Company by BioNTech ("BNTX") (NASDAQ: BNTX). Under the terms of the acquisition agreement, NTGN shareholders will receive 0.063 American Depositary Shares issued by BNTX ("ADS") (each ADS representing one ordinary share of BNTX) in exchange for each share of NTGN common stock that they own. At the consummation of the proposed acquisition, NTGN will merge with Endor Lights, Inc., a wholly-owned subsidiary of BNTX, and itself become a wholly-owned subsidiary of BNTX.
WILMINGTON, Del., April 21, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Neon Therapeutics, Inc. (NASDAQ GS: NTGN) regarding possible breaches of.
WILMINGTON, Del., March 24, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Forty Seven, Inc. (NASDAQ GS: FTSV) regarding possible breaches of fiduciary.
Neon Therapeutics, Inc. (NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority (DHA) for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01. Neon’s initial Phase 1 clinical trial of NEO-PTC-01 will be in patients with metastatic melanoma who are not responsive to checkpoint inhibitors. NEO-PTC-01 is a personal neoantigen-targeted T cell therapy candidate derived from patients’ peripheral blood mononuclear cells (PBMCs) and consisting of multiple T cell populations targeting the most therapeutically relevant neoantigens from each patient’s tumor.
NEW YORK, NY / ACCESSWIRE / March 4, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP ...
Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-03033 on behalf of shareholders of Neon Therapeutics, Inc. ("Neon" or the "Company") (NASDAQ:NTGN) who have been harmed by Neon's and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with BioNTech SE (the "Proposed Transaction").
NEW YORK, March 12, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders..
NEW YORK, March 24, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders..
NEW YORK, March 23, 2020 -- Neon Therapeutics, Inc. (NTGN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale.
WILMINGTON, Del., March 09, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: The Meet Group, Inc. (NASDAQ GS: MEET) regarding possible breaches of.
BALA CYNWYD, PA / ACCESSWIRE / March 3, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other ...
Merger activity continued to remain lackluster last week. Northwest Bancshares (NWBI) completed the acquisition of MutualFirst Financial (MFSF). KEMET Corporation (KEM) received approval from the Committee on Foreign Investment in the United S…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2020 financial results and provided an update on the Company, including its first quarter progress with IPI-549, the Company’s first-in-class, o…
WILMINGTON, Del., April 02, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: FGL Holdings (NYSE: FG) regarding possible breaches of fiduciary duties and.
NEW YORK, March 11, 2020 -- Neon Therapeutics, Inc. (NASDAQ:NTGN) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with.
NEW YORK, April 17, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.